Table of Contents

Table of Contents

VOLUME 1

Preface

Micro- and Nano-Particulate Drug Delivery Systems for Cancer Treatment;pp. 1-82
(Jose L. Arias – Dept. of Pharmacy and Pharmaceutical Technology, Univ. of Granada, Granada, Spain)

Geldanamycin Derivatives as Promising Anticancer Drugs: Therapy via Hsp90 Inhibition;pp. 83-108
(Alexander E. Kabakov – Dept. of Radiation Biochemistry, Medical Radiology Research Center, Obninsk, Russia)

Synergistic Antitumor Activity of Metronomic Dosing Chemotherapy in Combination with Liposomal Anticancer Drug;pp. 109-138
(Tatsuhiro Ishida, Hiroshi Kiwada – Dept. of Pharmacokinetics and Biopharmaceutics, Univ. of Tokushima, Sho-machi, Tokushima, Japan)

Organotin Polyethers as Anticancer Drugs;pp. 139-163
(Charles E. Carraher, Jr., Michael R. Roner, Girish Barot – Florida Atlantic Univ., Dept. of Chemistry and Biochemistry, Boca Raton, FL and others)

Studies on Anticancer Agents: Phenolic Compounds and their Pharmacological Activity;pp. 165-190
(Maria Dolors Pujol, Isabel Sanchez – Laboratori de Quimica Farmaceutica, Univ. de Barcelona, Barcelona, Spain)

Design of Novel Anticancer Drugs Utilizing Busulfan for Optimizing Pharmacological Properties and Pattern Recognition Techniques for Elucidation of Clinical Efficacy;pp. 191-206
(Ronald Bartzatt – Univ. of Nebraska, Chemistry Department, Omaha, NE, USA)

Analysis of Associations Among Novel Property Descriptors and their Capacity in Determining Clinical Efficacy by Utilizing Pattern Recognition Technigues;pp. 207-222
(Ronald Bartzatt – Univ. of Nebraska, Chemistry Department, Omaha, NE, USA)

Insights into the Mode of Action of Bioreductive Ruthenium(III) Cytotoxins from Electrochemical and Biological Studies;pp. 223-234
Erwin Reisner – Univ. of Oxford, Inorganic Chemistry Laboratory, Oxford, UK)

Marina Crystal Minerals(MCM) Induce Apoptosis of Human Metastatic Breast Cancer MDA-MB-231 Cells In Vitro;pp. 235-243
(Mamdooh Ghoneum, Takeshi Ogura, Sastry Gollapudi- Dept. of Otolaryngology, Drew Univ. of Medicine and Science, Los Angeles, CA, USA and others)

Anti-Estrogen Agents: Aromatase Inhibitors; Past, Present and Future;pp. 245-262
(Masanori Shimodaira, and Tomohiro Nakayama, Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan, and others)

Aromatase Inhibitors: Types, Mode of Action and Indications;pp. 263-280
(Helena Aguilar, MD, and Ander Urruticoechea, MD., Ph.D., Institut Català d’Oncologia. Barcelona. Spain)

Aromatase Inhibitors;pp. 281-295
(Mosammat Rashida Begum, Maruf Siddiqui, Dhaka Medical College and Hospital, Dhaka, Bangladesh)

Upfront vs. Sequential Aromatase Inhibitors: An Ongoing or Settled Debate?;pp. 297-314
(Tallal Younis and Chris Skedgel, Queen Elizabeth II Health Sciences Centre, Department of Medicine at Dalhousie University, Halifax, Nova Scotia, and others)

Aromatase Expression in the Endometrium and its Role in the Development of Uterine Pathology;pp. 315-332
(Hugo Maia Jr., Julio Casoy, Jorge Valente Filho and Elsimar Coutinho.
Centro de Pesquisas e Assistência em Reprodução Humana (CEPARH)
Salvador, Bahia, Brazil)

Aromatase Inhibitors for the Medical Treatment of Endometriosis;pp. 333-348
(Kaei Nasu, Akitoshi Tsuno, Akitoshi Yuge, Masakazu Nishida, Hisashi Narahara,
Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan)

VOLUME 2

An Update of the Use of Aromatase Inhibitors in the Management of Breast Cancer
(S. Tang, D.A.L. Morgan, K.L. Cheung, Division of Breast Surgery, University of Nottingham, Department of Oncology, Nottingham University Hospitals, UK)

Aromatase Inhibitors in Ovulation Induction: Myth or Reality?
(Nikolaos P. Polyzos, Spyridon Tzioras, Davide Mauri, Maria Tsappi, Antonis Valachis, Charalambos Dritsas, Kamposioras Konstantinos, Charalambos Panou, Lamprini Tsali,
Panhellenic Association for Continual Medical Research (PACMeR), Section of Obstetrics and Gynaecology, Bolos, Greece)

The Use of Aromatase Inhibitors in Ovarian Cancer and Identification of Responsive Tumors
(S.P. Langdon, G. Walker, D. Faratian, C. Gourley, A.R.W. Williams, I. Um, J.F. Smyth, D.J. Harrison, Edinburgh Breakthrough Breast Unit, Institute for Genetics and Molecular Medicine, University of Edinburgh, United Kingdom)

Therapeutic Implications of the Intrinsic and Acquired Resistance of Cancer Stem/Progenitor Cells in Inefficacy of Current Cancer Treatments and Disease Relapse
(Murielle Mimeault and Surinder K. Batra, Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska)

Role of O6-methyl guanine-DNA methyl transferase and the effect of O6-benzylguanine in cancer chemotherapy
(Jun Murakami, Jun-ichi Asaumi, Hidetsugu Tsujigiwa, Masao Yamada, Susumu Kokeguchi, Hitoshi Nagatsuka, Tatsuo Yamamoto, You-Jin Lee, 1Department of Oral and Maxillofacial Radiology, Okayama University, Okayama, Japan, et al.)

The Role of Tumoural Micro-Environment and its Vasculature on Chemotherapy Drug Resistance: The Potential for it’s Modulation to Achieve Therapeutic Gain
(A. Weickhardt, M. Michael, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia)

Inherent and Microenvironment-Mediated Mechanisms of Drug Resistance
(Malathy P.V Shekhar, Breast Cancer Program, Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan)

Studies on the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitor Gefitinib in NSCLC Cell Lines: Evidence that Ligand-Induced Endocytosis of EGFR via the Early/Late Endocytic Pathway is Associated with Gefitinib Sensitivity of NSCLC Cell Line
(Yukio Nishimura, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan)

Mechanisms of resistance to EGF receptor-tyrosine kinase inhibitor in NSCLC cell lines: Gefitinib sensitivity is closely correlated with ligand-induced endocytosis of phosphorylated EGF receptor
(Yukio Nishimura, Kiyoko Yoshioka, Kazuyuki Itoh, 1Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, and others)

Targeting Adverse Features of Hormone-Resistant Breast Cancer
(Stephen Hiscox, Liam Morgan, Nicola Jordan, Julia Gee, Robert I Nicholson, Welsh School of Pharmacy, Cardiff University, Cardiff, UK)

Systematic Analysis of Patterns of Cross Resistance between Anticancer Agents
(Britta Stordal and Ross Davey, National Institute for Cellular Biotechnology, Dublin City University, Ireland, and others)

Molecular Structure and Energy: Clinical Importance in Drug Resistant Neoplasms
(Viroj Wiwanitkit, Wiwanitkit House, Bangkhae, Bangkok, Thailand)

Treating Drug Resistant Malignancy
(Viroj Wiwanitkit, Wiwanitkit House, Bangkhae, Bangkok, Thailand)

Overcoming Ovarian Cancer Drug Resistance with Phytochemicals and Other Compounds
(Marion M. Chan, Temple Univ. School of Medicine, Dept. of Microbiology and Immunology, Philadelphia, PA, Dunne Fong, The State Univ. of New Jersey, Dept. of Cell Biology and Neuroscience, Piscataway, NJ)

New Research Communications on Cancer Drug Resistance, Assessment of cancer drug resistance with nuclear medicine images
(Seigo Kinuya, Dept. of Biotracer Medicine,Kanazawa University Graduate School of Medical Sciences,Kanazawa,Japan)

Index